<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Workshop identified 48 unselected patients with therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and inv(16), and 41 patients with t(15;17) after chemotherapy (CT) and/or radiotherapy (RT) for a malignant or nonmalignant disease </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary diseases</z:e> were: <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, 33 patients; <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 24 patients; various other <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, 30 patients; and nonmalignant diseases, 2 patients </plain></SENT>
<SENT sid="2" pm="."><plain>The general type of previous therapy was RT only in 10 patients with an inv(16) and in 12 patients with a t(15;17), <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> plus <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> in 24 patients with an inv(16) and in 18 patients with a t(15;17), <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> only in 5 patients with an inv(16) and in 2 patients with a t(15;17), <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> only in 6 patients in each subgroup, and other types of chemotherapy in 3 patients in each subgroup </plain></SENT>
<SENT sid="3" pm="."><plain>Most CT-treated patients (69%) also received RT </plain></SENT>
<SENT sid="4" pm="."><plain>The latency period to development of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was short: a median of 22 months in patients with inv(16) and 29 months in patients with t(15;17) </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-six patients (54%) with an inv(16) and 17 patients (41%) with a t(15;17) had additional cytogenetic abnormalities, which were unrelated to age and survival in both subgroups </plain></SENT>
<SENT sid="6" pm="."><plain><z:mp ids='MP_0004027'>Trisomy</z:mp> of chromosomes 8, 21, and 22 and del(7q) were the most frequent additional abnormalities in the inv(16) subgroup, whereas +8, -5, and del(16q) were most frequent in the t(15;17) subgroup </plain></SENT>
<SENT sid="7" pm="."><plain>The disease was overt t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in 38/48 patients (79%) with an inv(16) and in 38/41 patients (93%) with a t(15;17) </plain></SENT>
<SENT sid="8" pm="."><plain>Thirty-three of 39 intensively treated patients (85%) with an inv(16) obtained a complete remission, whereas 24 of 35 intensively treated patients (69%) with a t(15;17) obtained a complete remission </plain></SENT>
<SENT sid="9" pm="."><plain>The median overall survival of intensively treated patients was 29 months in both cytogenetic subgroups </plain></SENT>
<SENT sid="10" pm="."><plain>In the inv(16) subgroup, patients younger than 55 years of age had a longer survival when compared with older patients (P = 0.006) </plain></SENT>
<SENT sid="11" pm="."><plain>The study supports the observation that t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with inv(16) and t(15;17) is often associated with prior therapy with <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi>; however, a notable finding was the high frequency of treatment with only radiotherapy, 29% of t(15;17) and 21% of inv(16) </plain></SENT>
<SENT sid="12" pm="."><plain>Response rates to intensive chemotherapy in this study were comparable to those of de novo disease </plain></SENT>
</text></document>